Phase I, Open-Label, Non-Placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI as First or Second Line Therapy in Patients With Metastatic Colorectal.

Trial Profile

Phase I, Open-Label, Non-Placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI as First or Second Line Therapy in Patients With Metastatic Colorectal.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2014

At a glance

  • Drugs Regorafenib (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 15 May 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
    • 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 May 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003663).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top